Galeterone FDA Approval Status
FDA Approved: No
Generic name: galeterone
Company: Tokai Pharmaceuticals, Inc.
Treatment for: Prostate Cancer
Galeterone (TOK-001) is an androgen receptor antagonist and CYP17 lyase inhibitor in development for the treatment of metastatic castration-resistant prostate cancer (CRPC).
Development Timeline for galeterone
|Jun 12, 2012||Tokai Pharmaceuticals' Galeterone Receives Fast Track Designation from the FDA for the Treatment of Advanced Prostate Cancer|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.